Cargando…

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy

We report our experience with the use of intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive infants screened at a single centre over 18 months. Intravitreal ranibizumab was offered in selected cases requiring treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Joyce J. T., Lam, Carol P. S., Kwok, Madeline K. M., Wong, Raymond L. M., Lee, Gary K. Y., Lau, Winnie W. Y., Yam, Jason C. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891718/ https://www.ncbi.nlm.nih.gov/pubmed/27256987 http://dx.doi.org/10.1038/srep27082

Ejemplares similares

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab
por: Tong, Qizhe, et al.
Publicado: (2018)

Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012)

Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query
por: Al Kalbani, Khulood, et al.
Publicado: (2023)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo, Odalis, et al.
Publicado: (2015)

Combination therapy of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity
por: Dudani, Ajay I, et al.
Publicado: (2022)

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
por: Huang, Qiujing, et al.
Publicado: (2017)

Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity
por: Zhao, Jinfeng, et al.
Publicado: (2020)

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
por: Menke, Marcel N, et al.
Publicado: (2015)

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016)

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity
por: Gangwe, Anil Babanrao, et al.
Publicado: (2021)

Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)

Intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight infant with rush type retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2012)

COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019)

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis(®))
por: Horowitz, Soraya Alessandra, et al.
Publicado: (2020)

Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity
por: Parchand, Swapnil M, et al.
Publicado: (2021)

Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
por: Wu, Lei, et al.
Publicado: (2023)

Effect of ranibizumab on retinopathy of prematurity: A meta-analysis
por: Wang, Zhibin, et al.
Publicado: (2022)

Treatment of Intravitreal Ranibizumab Resistant Radiation Retinopathy with Intravitreal Dexamethasone Implant: A Case Report
por: Sabaner, Mehmet Cem, et al.
Publicado: (2022)

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity
por: Chandra, Parijat, et al.
Publicado: (2019)

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023)

Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
por: Alva, Niza, et al.
Publicado: (2023)

Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment
por: Dong, Feng, et al.
Publicado: (2016)

Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy
por: Xu, Jun, et al.
Publicado: (2020)

Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography
por: Al Rasheed, Raghad, et al.
Publicado: (2022)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study
por: Hu, Qinrui, et al.
Publicado: (2017)

Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity
por: Cao, Jing-Ke, et al.
Publicado: (2023)

Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment
por: Gotz-Więckowska, Anna, et al.
Publicado: (2017)

Comparison of intravitreal injection of ranibizumab versus bevacizumab for treatment of type 1 and aggressive retinopathy of prematurity in rural Egypt. A randomized clinical trial
por: Tawfik, Ghada Mahmoud, et al.
Publicado: (2022)

Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity
por: Vedantham, Vasumathy
Publicado: (2019)

Endophthalmitis in Retinopathy of Prematurity after Intravitreal Aflibercept Injection
por: Suren, Elcin, et al.
Publicado: (2020)

Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain
por: Obata, Shumpei, et al.
Publicado: (2021)

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
por: Chen, Yen-Chih, et al.
Publicado: (2018)

Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Combined with Posterior Subtenon Triamcinolone Acetonide in Diabetic Macular Edema
por: Karatas, Gamze, et al.
Publicado: (2021)

Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report
por: Mitropoulos, Panagiotis G., et al.
Publicado: (2014)

Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma
por: H.Y. Wu, Zenith, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d08gpdtputcjmui63u1ns5n17d